Sterling Capital Management LLC Has $2.76 Million Holdings in Jazz Pharmaceuticals PLC $JAZZ

Posted by George Bondi on Jun 29th, 2026

Sterling Capital Management LLC lessened its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Free Report) by 16.3% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 14,615 shares of the specialty pharmaceutical company’s stock after selling 2,843 shares during the period. Sterling Capital Management LLC’s holdings in Jazz Pharmaceuticals were worth $2,763,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in JAZZ. Dimensional Fund Advisors LP boosted its position in Jazz Pharmaceuticals by 11.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,836,652 shares of the specialty pharmaceutical company’s stock valued at $373,855,000 after buying an additional 298,815 shares during the last quarter. Capital World Investors raised its position in shares of Jazz Pharmaceuticals by 4.4% during the fourth quarter. Capital World Investors now owns 2,666,602 shares of the specialty pharmaceutical company’s stock worth $453,322,000 after acquiring an additional 111,735 shares during the last quarter. Ameriprise Financial Inc. lifted its stake in shares of Jazz Pharmaceuticals by 11.4% during the second quarter. Ameriprise Financial Inc. now owns 1,867,399 shares of the specialty pharmaceutical company’s stock valued at $198,159,000 after acquiring an additional 191,637 shares during the period. Franklin Resources Inc. lifted its stake in shares of Jazz Pharmaceuticals by 164.0% during the fourth quarter. Franklin Resources Inc. now owns 1,818,911 shares of the specialty pharmaceutical company’s stock valued at $309,215,000 after acquiring an additional 1,129,995 shares during the period. Finally, Fuller & Thaler Asset Management Inc. boosted its holdings in Jazz Pharmaceuticals by 3.1% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 1,677,132 shares of the specialty pharmaceutical company’s stock valued at $285,113,000 after acquiring an additional 50,996 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ JAZZ opened at $230.02 on Monday. Jazz Pharmaceuticals PLC has a twelve month low of $105.00 and a twelve month high of $243.32. The stock has a market cap of $14.45 billion, a price-to-earnings ratio of -11,495.25, a P/E/G ratio of 0.20 and a beta of 0.32. The company has a quick ratio of 1.85, a current ratio of 2.04 and a debt-to-equity ratio of 0.95. The company’s fifty day moving average is $224.42 and its 200-day moving average is $192.80.

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last released its quarterly earnings data on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 EPS for the quarter. The business had revenue of $1.07 billion during the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. Equities research analysts predict that Jazz Pharmaceuticals PLC will post 22.09 EPS for the current year.

Insider Transactions at Jazz Pharmaceuticals

In other news, Director Rick E. Winningham sold 2,741 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $241.57, for a total transaction of $662,143.37. Following the transaction, the director owned 9,567 shares in the company, valued at $2,311,100.19. The trade was a 22.27% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Bruce C. Cozadd sold 6,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $190.50, for a total value of $1,143,000.00. Following the completion of the transaction, the director owned 384,682 shares of the company’s stock, valued at $73,281,921. This represents a 1.54% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 13,098 shares of company stock valued at $2,832,086. Insiders own 4.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on JAZZ shares. Wells Fargo & Company lifted their price objective on Jazz Pharmaceuticals from $250.00 to $265.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Weiss Ratings lowered shares of Jazz Pharmaceuticals from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, June 12th. Bank of America lifted their price target on shares of Jazz Pharmaceuticals from $281.00 to $307.00 and gave the stock a “buy” rating in a research report on Wednesday, June 10th. UBS Group raised shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $188.00 to $307.00 in a research note on Tuesday, May 19th. Finally, Truist Financial set a $256.00 price target on shares of Jazz Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, June 9th. Sixteen equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $246.06.

Check Out Our Latest Research Report on JAZZ

Jazz Pharmaceuticals Company Profile

(Free Report)

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.